No abstract

Cardiovascular disease is the leading cause of mortality in the United States, accounting for one fourth of deaths. Higher rates of obesity put Hispanic and Black men at increased risk. The American Heart Association cites diet quality, physical activity, and body weight as alterations responsive to health promotion intervention. Prevention strategies need to begin in adolescence and the emerging adulthood years to impact cumulative risk factors. A scoping review identified search terms and this was followed by a systematic review of Cumulative Index to Nursing and Allied Health Literature (CINAHL) and PubMed databases for articles published in English from January 1, 2002, through May 11, 2017. This review explores community-based content, delivery, recruitment, or retention strategies used with young men of color aged 15 to 24 years. Of 17 articles describing 16 individual interventions and 1 describing multiple interventions (with samples ranging from 37 to 4,800), 13 reported significant results in one or more domains. No studies specifically targeted the needs of young men and only three had more than 50% male participants. There was a gap in studies that addressed young men in the ages of interest with most interventions reaching participants aged 11 to 19 years. Cultural tailoring was addressed through recruitment setting, interventionist characteristics, community involvement, and theoretical frameworks such as motivational interviewing that allow individual goal setting. Because young men seek access to preventive health services less than young women, it is suggested that interventions that are community based or use push technology (send information directly to the user) be increased.

No abstract

No abstract

Age-related metabolic diseases, such as CVD and diabetes (prediabetes and insulin resistance), are major contributors to morbidity, mortality, and healthcare costs, which are now estimated at over $350 billion per year in direct expenditures (National Assoc. Biomedical Res, 2016). Biomarkers are essential to diagnosis and manage these common diseases. Yet, clinical indicators such as HbA1C, fasting glucose, and insulin vary widely over time when measured at various (CLIA) labs and should not be the sole drivers to diagnose, monitor, or intervene, particularly when using pharmaceuticals. 100 subjects were assessed with FG, insulin, and HbA1C through two reputable labs for each of two sets of lab tests (Draws 1 and 2). The samples were taken from the same blood draw, identical protocol, procedure and shipping. Significant differences were found (p<.05) between all 3 biomarkers at 2 points in time, separated by 4 to 6 months. When comparing deltas between the two time points, there significant differences in absolute values. Moreover, the direction of the delta was inconsistent between labs. In some subjects, the biomarkers in Lab A revealed increases in FG, insulin, and/or HbA1C, while Lab B showed decreases in the same values drawn at precisely the same time and handled identically. The differences documented between two labs were not systematic, and clinically challenging to interpret. Differences in deltas were even more dramatic when using separate labs for Draws 1 and 2. The choice of laboratory significantly impacts diagnosis and interventions, ultimately impairing accurate outcomes and limiting informed decision-making. Laboratory options are typically dictated by variables outside of the physician control, such as insurance coverage, location, and practice policies. These inter-laboratory variations must be taken into consideration when exploring therapeutic management. Lack of biomarker precision highlights the need for a deeper understanding of alternative modalities to monitor patients with disorders of aging, adaptable advances that are synergistic to biomarkers, such as wearable continuous glucose monitors, and education to lead awareness on the part of clinician with respect to choices in partnering their patients. Unless otherwise noted, all abstracts presented at ENDO are embargoed until the date and time of presentation. For oral presentations, the abstracts are embargoed until the session begins. Abstracts presented at a news conference are embargoed until the date and time of the news conference. The Endocrine Society reserves the right to lift the embargo on specific abstracts that are selected for promotion prior to or during ENDO.